Beauvericin
(Synonyms: 白僵菌素) 目录号 : GC17342白僵菌素(Beauvericin)是一种环状十六缩酚肽霉菌毒素,是酰基辅酶 A:胆固醇酰基转移酶 1(ACAT1)的有效抑制剂,参与多种肿瘤相关途径。
Cas No.:26048-05-5
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment [1]: | |
Cell lines | CHO-K1 cells |
Preparation Method | CHO-K1 cells were cultured at 2x104 cells/well in 96-well microplates and grown to confluence (65%). The medium was removed and replaced with fresh medium containing different concentrations of Beauvericin (0.625, 1.25, 2.5, 5, 10, and 20µM). Cytotoxicity was measured at 24, 48, and 72h using the MTT assay. |
Reaction Conditions | 0.625, 1.25, 2.5, 5, 10, and 20µM; 24, 48 and 72h |
Applications | The IC50 values obtained in CHO-K1 cells were 10.7±3.7, 2.5±3.3 and 2.2±3.3μM after 24, 48 and 72h of Beauvericin exposure, respectively. |
Animal experiment [2]: | |
Animal models | Female BALB/c mice |
Preparation Method | Mice were sensitized by painting 100µL of 1% 2,4,6-trinitrobenzene sulfonic acid(TNBS) in ethanol onto the shaved skin of their abdomens 7 days before challenge. On the day of challenge, the mice were fasted for 20h before the injection. A 3.5 F catheter was then carefully inserted through the anus into the colon; the tip was placed 4 cm from the anus. They were given 100µL of 0.5% TNBS slowly injected into the lumen of the colon via a catheter fitted to a 1mL syringe. In the sham control, mice received 50% ethanol only. The animals were kept vertical for 30s, allowing TNBS and/or ethanol to permeate the entire colon, including the caecum and appendix, and then returned to their cages. Beauvericin (1, 2 or 4mg/kg) and dexamethasone (1mg/kg) were administered intraperitoneally once daily from day 0 to day 7. TNBS control mice received PBS alone. The animals were monitored once daily for weight, water, food consumption, morbidity, stool consistency, and the presence of blood in the feces and at the anus. |
Dosage form | 1, 2 or 4mg/kg; i.p. |
Applications | Beauvericin attenuated TNBS-induced colitis. Beauvericin inhibited pathological changes in TNBS-induced colitis. Beauvericin suppressed T cell infiltration into colonic tissue. Beauvericin treatment significantly reduced the levels of cytokines IFN-γ, TNF-α, IL-1β, and IL-12. |
References: [1]Mallebrera B, Juan-Garcia A, Font G, et al. Mechanisms of beauvericin toxicity and antioxidant cellular defense[J]. Toxicology Letters, 2016, 246: 28-34. [2]Wu X F, Xu R, Ouyang Z J, et al. Beauvericin ameliorates experimental colitis by inhibiting activated T cells via downregulation of the PI3K/Akt signaling pathway[J]. PloS one, 2013, 8(12): e83013. |
Beauvericin is a cyclic hexadecanopeptide mycotoxin and a potent inhibitor of acyl-CoA:cholesterol acyltransferase 1 (ACAT1), which is involved in multiple tumor-related pathways[1]. Beauvericin has potential antifungal activity and is a potent inhibitor of CYP3A1/2 enzymes in human and rat liver microsomes[2]. Beauvericin also has significant inhibitory effects on CYP3A4/5 and CYP2C19, with IC50 values of 1.2μM and 1.3μM, respectively[2]. Beauvericin is active against Gram-positive bacteria and mycobacteria, and can also induce programmed cell death in mammals[3].
In vitro, treatment of CHO-K1 cells with Beauvericin (0.625-20µM) for 24-72h reduced cell viability in a dose- and time-dependent manner, altered the mitochondrial membrane potential in the cells, arrested the G0/G1 phase of the cell cycle and produced apoptosis, and increased catalase and superoxide dismutase activities[4]. Beauvericin (3.125-25µM) treated human colon adenocarcinoma Caco-2 cells for 24-72h reduced cell viability in a dose- and time-dependent manner, increased apoptosis and mitochondrial damage, and DNA damage was observed after 12μM[5]. Beauvericin (0-10µM) treated immature dendritic cells, mature dendritic cells and macrophages with IC50 values of 1.0μM, 2.9μM and 2.5μM, respectively [6].
In vivo, Beauvericin (4mg/kg) was used to treat colitis mice by intraperitoneal injection, which inhibited the pathological changes of colitis, suppressed T cell infiltration into colon tissue, and significantly reduced the levels of cytokines IFN-γ, TNF-α, IL-1β and IL-12[7].
References:
[1] Zhou H, Zhang J, Chen X, et al. Potent Anticancer Activities of Beauvericin Against KB Cells In Vitro by Inhibiting the Expression of ACAT1 and Exploring Binding Affinity[J]. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 2022, 22(5): 897-904.
[2] Mei L, Zhang L, Dai R. An inhibition study of beauvericin on human and rat cytochrome P450 enzymes and its pharmacokinetics in rats[J]. Journal of enzyme inhibition and medicinal chemistry, 2009, 24(3): 753-762.
[3] Olleik H, Nicoletti C, Lafond M, et al. Comparative structure–activity analysis of the antimicrobial activity, cytotoxicity, and mechanism of action of the fungal cyclohexadepsipeptides enniatins and beauvericin[J]. Toxins, 2019, 11(9): 514.
[4] Mallebrera B, Juan-Garcia A, Font G, et al. Mechanisms of beauvericin toxicity and antioxidant cellular defense[J]. Toxicology Letters, 2016, 246: 28-34.
[5] Prosperini A, Juan-García A, Font G, et al. Beauvericin-induced cytotoxicity via ROS production and mitochondrial damage in Caco-2 cells[J]. Toxicology letters, 2013, 222(2): 204-211.
[6] Ficheux A S, Sibiril Y, Parent-Massin D. Effects of beauvericin, enniatin b and moniliformin on human dendritic cells and macrophages: An in vitro study[J]. Toxicon, 2013, 71: 1-10.
[7] Wu X F, Xu R, Ouyang Z J, et al. Beauvericin ameliorates experimental colitis by inhibiting activated T cells via downregulation of the PI3K/Akt signaling pathway[J]. PloS one, 2013, 8(12): e83013.
白僵菌素(Beauvericin)是一种环状十六缩酚肽霉菌毒素,是酰基辅酶 A:胆固醇酰基转移酶 1(ACAT1)的有效抑制剂,参与多种肿瘤相关途径[1]。Beauvericin有潜在的抗真菌活性,并且是人和大鼠肝微粒体中CYP3A1/2酶的有效抑制剂[2]。Beauvericin对CYP3A4/5和CYP2C19也有显著的抑制作用,IC50值分别为1.2μM和1.3μM[2]。Beauvericin对革兰氏阳性菌和分枝杆菌具有活性,并且还能够诱导哺乳动物的程序性细胞死亡[3]。
在体外,Beauvericin(0.625-20µM)处理CHO-K1细胞24-72h,以剂量和时间依赖性方式降低细胞活力,改变了细胞中的线粒体膜电位,使细胞周期的G0 /G1期停滞并产生细胞凋亡,增加了过氧化氢酶和超氧化物歧化酶活性[4]。Beauvericin(3.125-25µM)处理人结肠腺癌Caco-2细胞24-72h,以剂量和时间依赖性方式降低细胞活力,增加了细胞凋亡和线粒体破坏,12μM后观察到 DNA损伤[5]。Beauvericin(0-10µM)处理未成熟树突状细胞、成熟树突状细胞和巨噬细胞,IC50分别为1.0μM、2.9μM和2.5μM [6]。
在体内,Beauvericin(4mg/kg)通过腹腔注射治疗结肠炎小鼠,抑制了结肠炎的病理变化,抑制了T细胞浸润到结肠组织,显著降低了细胞因子IFN-γ、TNF-α、IL-1β和IL-12的水平[7]。
Cas No. | 26048-05-5 | SDF | |
别名 | 白僵菌素 | ||
化学名 | (3S,9S,15S)-3,9,15-tribenzyl-6,12,18-triisopropyl-4,10,16-trimethyl-1,7,13-trioxa-4,10,16-triazacyclooctadecane-2,5,8,11,14,17-hexaone | ||
Canonical SMILES | CC(C(OC([C@](N(C(C(O1)([H])C(C)C)=O)C)([H])CC2=CC=CC=C2)=O)([H])C(N([C@@](C(OC(C(N([C@@](C1=O)([H])CC3=CC=CC=C3)C)=O)([H])C(C)C)=O)([H])CC4=CC=CC=C4)C)=O)C | ||
分子式 | C45H57N3O9 | 分子量 | 783.95 |
溶解度 | DMF: 30 mg/ml; DMSO: 30 mg/ml; Ethanol: 30 mg/ml; Ethanol:PBS (pH 7.2)(1:2): 0.3 mg/ml | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.2756 mL | 6.378 mL | 12.7559 mL |
5 mM | 0.2551 mL | 1.2756 mL | 2.5512 mL |
10 mM | 0.1276 mL | 0.6378 mL | 1.2756 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。